SLC9A1 and breast cancer: Cariporide significantly decreased NHE1 expression in breast cancer cells (Fig. 2e, f), where it inhibited the proliferation of MCF-7 and MCF-7/ADR cells in a dose- and time- dependent manner, as assessed by CCK8 assays with a range of concentrations (Fig. 2a), of doxorubicin (Fig. 2b) or paclitaxel (Fig. 2c) in culture for 24 and 48 h.